Régulation intelligente pour villes intelligentes: Quel aménagement urbain, quelles lois pour l’innovation sociale à Montréal?
For the past seven years, the Canada Europe Transatlantic Dialogue (CETD) has been examining different aspects of the public dimensions of Canada – EU relations.
CIPP/Lallemand seminar with Nicolas Binctin, Associate Professor, Faculty of Law at the Universities of Poitiers, Paris II, and Paris 12 UPEC.
The Regroupement Droit, Changements et Gouvernance (www.rdcg.org) has the pleasure of welcoming Eliza Bateman (DCL/PhD Candidate, Faculty of Law, McGill University) for the February Midi-confé
Soeur Monique, from the Hospital Santa Marcelina in Sao Paolo, Brazil, and alumni of the Department of Family Medicine, met with Dr. Bergevin, Dr. Juras, Dr. Connolly, Dr. Bergman, and Ms. Simmons on January 5th. The meeting covered a new partnership between the Department and Santa Marcellna’s new medical school. This partnership will include a version of the Blended Learning Education Program in Faculty Development, a new MSc.
We invite you to Professor Fabien Gélinas' Inaugural Lecture as holder of the Sir William C. Macdonald Chair.
See document attached (in French only).
Table ronde « Perspectives sur le droit de la famille contemporain » et lancement du Dictionnaire de droit privé et lexiques bilingues — Les familles
The Paul-André Crépeau Centre for Private and Comparative Law is happy to officially invite you, in collaboration with the Chaire du notariat de l’Université de Montréal, to a panel entitled “Perspectives sur le droit de la famille contemporain” t
The Childhood Anxiety and Regulation of Emotions (C.A.R.E.) Research Group is a new laboratory operation under the direction of Dr. Tina Montreuil, Department of Educational and Counselling Psychology. Researchers at C.A.R.E.
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.